News Stories

Esperion has announced that NEXLETOL™ (bempedoic acid) is now available in pharmacies in the United States. NEXLETOL is an oral, once-daily, tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.

MINNEAPOLIS, MN – (Sept. 14, 2019) – A comprehensive review of scientific evidence that analyzes the impact of low-carbohydrate and very-low-carbohydrate diets (including ketogenic diets) on cardiometabolic risk factors and body weight was released today by the National Lipid Association (NLA).

For patients 45 years of age or older with clinical ASCVD, or 50 years of age or older with type 2 diabetes requiring medication and > 1 additional risk factor, and fasting triglycerides 135-499 mg/dL on maximally tolerated statin, with or without exetimibe, treatment with icosapent ethyl is recommended for ASCVD risk reduction.